Avelas Is A Clinical Stage Drug Device Company Pioneering The Field Of Fluorescence Imaging For Real Time Cancer Detection Avelas Is Focused On The Development And Commercialization Of Pegloprastidealso Referred To Asavb 620A Novel Fluorescent Imaging Agent Used In Combination With A Fluorescence Camera System For Real Time Cancer Detection And Visualization During Surgerythe Goal Of Intraoperative Image Guided Surgery With Pegloprastide Is To Increase The Precision Of Cancer Surgery And Improve Treatment Outcomes For Patients By Fluorescently Identifying Cancerin Real Time During Surgeryon The Surfaces Of Excised Tissue Or Residual Cancer In The Tumor Bed Not Otherwise Detected By Surgeons And Potentially Left Behind In A Patient During An Operation In A Prospective Registration Study In A Broad Population Of Women With Primarynonrecurrent Breast Canceruse Of Pegloprastide During Breast Conserving Surgery Correctly Identified Cancer In Up To 75Of Women With Positive Margins Who Would Have Otherwise Been Candidates For A Reoperation Beyond Breast Canceravelas Has Plans To Explore The Use Of Pegloprastide In A Subset Of Other Non Breast Cancer Surgeriessuch As Ovariancolorectalhead And Neckmelanomaand Sarcoma Avelas Has Developed Pegloprastide Based On Its Molecular Delivery Platform Which Uses The Company S Proprietary Activatable Cell Penetrating Peptideacpptechnology And A Tumor S Inherent Pathological Biochemistry To Specifically Target Cancer Tissue And Deliver Fluorescent Cargo To Tumorsthe Founding Technology For Avelas Was Derived From The Lab Of 2008 Nobel Prize Laureatedrroger Ytsien At The University Of Californiasan Diegopegloprastide S Structureproperties And Acpp Delivery Technology Have Been Reported In Eleven Peer Reviewed Publications And Have Over 2 800 Citations In Other Medical Publications
